You are here

Combination Approaches

Because cancer is not a single disease, our approach to treatment cannot be “one size fits all.” At Pfizer Oncology, we believe that the future lies in novel, biologically rational combinations based on unique tumor characteristics.

We’re looking at multiple mechanisms and pathways that contribute to tumor growth and investigating both traditional and cutting-edge technologies to target these pathways.


UNDERSTANDING HOT AND COLD TUMOR STRATEGIES

Depending on the “temperature” of the tumor, researchers may activate, release the “brakes” on, or sustain the immune response—or use a combination of these approaches. To do this, they rely on different activators and inhibitors. The goal is to move T-cells inside the tumor, so the immune system can recognize cancer and mount a strong defense against it.

Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of April 2017.


SEARCHING FOR THE RIGHT COMBINATIONS

By building unique combinations of two or even three compounds that affect the immune system in different ways, we hope to address difficult-to-treat cancers that may not respond to currently approved immunotherapies.

Our double and triple approaches involve smart sequencing of IO molecules with each other or with targeted or traditional compounds. Pfizer Oncology researchers are also at the forefront in exploring novel combination approaches to active IO agents.

EXAMPLES OF COMBINATIONS UNDER INVESTIGATION*

IO agent + IO agent

IO agent + targeted agent

IO agent + chemotherapy/radiation

IO agent + ADC

IO agent + vaccine/oncolytic virus

Other IO agents under investigation in various combinations

Chimeric antigen receptor T-cells (CAR-Ts)
Small molecule targeted agents
Bispecific antibodies

*Efficacy and safety of agents targeting these pathways are currently under investigation. Regulatory approval of any of these agents is dependent upon completion of the study programs and regulatory review by authorities. The clinical trial information is available at www.clinicaltrials.gov. This information is current as of April 2017.


 

Find out about Pfizer IO clinical trials

Find Pfizer IO clinical trials that are enrolling patients


At Pfizer we feel that, by combining established compounds with targeted agents, we can help a larger proportion of patients and be more successful.

- Dimitry Nuyten, MD, PhD Vice President, Immuno-Oncology